Unicycive Therapeutics, Inc. entered into an exchange agreement with accredited investors, surrendering shares of Series A-2 Preferred Stock in exchange for new preferred stock. They also filed Certificates of Elimination for their other preferred stock. The Amended Warrants and Exchange Agreement were filed as exhibits. The securities were issued without registration under the Securities Act.